Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dosing Strategy of Intravitreal Ranibizumab for Myopia Choroidal Neovascularization: a Single Center Randomized Prospective Study

NCT03042871 is registered in ClinicalTrials.gov with Zhongshan Ophthalmic Center, Sun Yat-sen University as lead sponsor.

NCT NCT03042871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03042871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dosing Strategy of Intravitreal Ranibizumab for Myopia Choroidal Neovascularization: a Single Center Randomized Prospective Study
Lead sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2015
Completion date
July 31, 2018
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

choroidal neovascularization